Panigrahi Balaji, Sharma Swati, Sitapara Bhakti, De Subrata, Nariya Mukesh
Ph.D. Scholar, Pharmacology Laboratory, Institute for Post Graduate Teaching and Research in Ayurveda, Gujarat Ayurved University, Jamnagar, Gujarat, India.
Ayu. 2019 Jul-Sep;40(3):185-191. doi: 10.4103/ayu.AYU_64_18. Epub 2020 Aug 8.
Bacnil capsule is a poly‑herbomineral formulation used to treat gastroenteritis. It contains many potential drugs derived from plant sources and (calcined fine powder) preparations.
The study was designed to ascertain the safety of bacnil capsule orally in Charle's Foster albino rats.
As per the Organization for Economic Cooperation and Development (OECD) 425 protocol oral acute toxicity study, bacnil capsule was administered orally once only at the dose of 2000 mg/kg in rats. For repeated dose toxicity study, AYUSH 170 and OECD 407, it was administered at three dose levels, Therapeutic doses (TED) (196.2), TED × 5 (981) and TED × 10 (1962) mg/kg/day orally for 28 days in albino rats followed by a 15‑day recovery period only on TED × 10 dose level.
Bacnil at the oral dose of 2000 mg/kg did not produce any toxicity or mortality in albino rats. Repeated dose 28‑day oral toxicity revealed that test formulation did not produce any significant change in serum biochemical, hematological, and histopathological parameters at therapeutic dose level. Mild‑to‑moderate pathological changes were observed in the various serum biochemical and cytoarchitecture of the liver, heart, kidney, and stomach at a dose of 10 TEDs; however, the same was reversed after discontinuation in the recovery test.
Bacnil at 196.2 mg/kg/day is safe at the therapeutic dose level in albino rats.
Bacnil胶囊是一种用于治疗肠胃炎的多草药矿物制剂。它含有许多源自植物的潜在药物以及(煅烧细粉)制剂。
本研究旨在确定Bacnil胶囊对查尔斯·福斯特白化大鼠口服给药的安全性。
按照经济合作与发展组织(OECD)425协议进行口服急性毒性研究,仅以2000 mg/kg的剂量对大鼠口服给予Bacnil胶囊一次。对于重复给药毒性研究,依据阿育吠陀170和OECD 407,在白化大鼠中以三个剂量水平口服给药28天,即治疗剂量(TED)(196.2)、TED×5(981)和TED×10(1962)mg/kg/天,仅在TED×10剂量水平给药后有15天的恢复期。
2000 mg/kg口服剂量的Bacnil在白化大鼠中未产生任何毒性或死亡。重复给药28天的口服毒性试验表明,在治疗剂量水平下,受试制剂在血清生化、血液学和组织病理学参数方面未产生任何显著变化。在10倍治疗剂量时,在肝脏、心脏、肾脏和胃的各种血清生化指标和细胞结构中观察到轻度至中度的病理变化;然而,在恢复试验中停药后这些变化得到逆转。
在白化大鼠中,196.2 mg/kg/天的Bacnil在治疗剂量水平是安全的。